Skip to main content

Osteonecrosis

2
Pipeline Programs
8
Companies
6
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Sandoz
SandozAustria - Kundl
2 programs
2
Zoledronic AcidPhase 21 trial
Zoledronic acidPhase 21 trial
Active Trials
NCT00781261Unknown120Est. Dec 2013
NCT00477217Withdrawn0Est. May 2009
Medacta
MedactaSwitzerland - Castel San Pietro
1 program
MOTO MedialN/A1 trial
Active Trials
NCT04072055Terminated150Est. Mar 2023
ETS
ETSMO - Rolla
1 program
Magnetic ResonanceN/A1 trial
Active Trials
NCT05684588Completed26Est. Oct 2023
Zimmer Biomet
Zimmer BiometFL - Jacksonville
1 program
Surgical approachN/A1 trial
Active Trials
NCT00913679Completed49Est. Nov 2020
Vericel
VericelCAMBRIDGE, MA
1 program
Ixmyelocel-TPHASE_31 trial
Active Trials
NCT00505219Completed11Est. Dec 2010

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
VericelIxmyelocel-T
SandozZoledronic Acid
SandozZoledronic acid
ETSMagnetic Resonance
MedactaMOTO Medial
Zimmer BiometSurgical approach

Clinical Trials (6)

Total enrollment: 356 patients across 6 trials

NCT00505219VericelIxmyelocel-T

Ixmyelocel-T Treatment of Patients With Osteonecrosis of the Femoral Head

Start: Sep 2007Est. completion: Dec 201011 patients
Phase 3Completed
NCT00781261SandozZoledronic Acid

Osteonecrosis of the Hip and Bisphosphonate Treatment

Start: Aug 2009Est. completion: Dec 2013120 patients
Phase 2Unknown
NCT00477217SandozZoledronic acid

Zoledronic Acid Treatment of Spontaneous Osteonecrosis of the Knee

Start: Jan 2008Est. completion: May 20090
Phase 2Withdrawn
NCT05684588ETSMagnetic Resonance

Post-COVID-19 Sequelae: Osteonecrosis of Femoral Head

Start: Nov 2021Est. completion: Oct 202326 patients
N/ACompleted
NCT04072055MedactaMOTO Medial

MOTO Post-marketing Surveillance Study

Start: Sep 2019Est. completion: Mar 2023150 patients
N/ATerminated
NCT00913679Zimmer BiometSurgical approach

A Comparison of Two Different Surgical Techniques in Hip Resurfacing Arthroplasty

Start: Nov 2008Est. completion: Nov 202049 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

8 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.